The move is significant for India’s generic injectable industry, where manufacturing lapses can pose a more immediate risk to patients than defects in medicines taken orally.
<iframe src="https://hindustansphere.com/embed/cluster/43ef8a14b5dab35ad861cc10b076b0fd8bdce8bc" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Govt plans central licensing for all sterile drugs after quality lapses"></iframe>
The move is significant for India’s generic injectable industry, where manufacturing lapses can pose a more immediate risk to patients than defects in medicines taken orally.
